Xalanol Side Effects

For latanoprost, the majority of adverse events relate to the ocular system which increased iris pigmentation, which may be permanent. For timolol, the most serious adverse events are systemic in nature, including bradycardia, arrhythmia, congestive heart failure, bronchospam and allergic reactions.
Like other topically applied ophthalmic drugs, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta blocking agents. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. Treatment related adverse events are listed as follows.
Adverse events are categorized by frequency as follows: very common, common, uncommon, rare and very rare.
Nervous system disorders: Uncommon: Headache.
Eye disorders: Very common: Increased iris pigmentation.
Common: Eye irritation (including stinging, burning and itching), eye pain.
Uncommon: Eye hyperaemia, conjunctivitis, vision blurred, lacrimation increased, blepharitis, corneal disorders.
Skin and subcutaneous tissue disorders: Uncommon: Skin rash, pruritus.
Additional adverse events have been reported specific to the use of the individual components of Xalanol.
For latanoprost, these are: Infections and infestations: Herpetic keratitis.
Nervous system disorders: Dizziness.
Eye disorders: Eyelash and vellus hair changes (increased length, thickness, pigmentation, and number), punctate epithelial erosions, periorbital oedema, iritis/uveitis, macular oedema (in aphakic, pseudophakic patients with torn posterior lens capsules or in patients with known risk factors for macular oedema), dry eye, keratitis, corneal oedema and erosions, misdirected eyelashes sometimes resulting in eye irritation, iris cyst, photophobia, periorbital and lid changes resulting in deepening of the eyelid sulcus.
Cardiac disorders: Aggravation of angina in patients with pre-existing disease, palpitations.
Respiratory, thoracic and mediastinal disorders: Asthma, asthma aggravation, dyspnoea.
Skin and subcutaneous tissue disorders: Darkening of palpebral skin.
Musculoskeletal and connective tissue disorders: Joint pain, muscle pain.
General disorders and administration site conditions: Chest pain.
For timolol, these are: Immune system disorders: Systemic allergic reactions including angioedema, urticaria, localised and generalised rash, pruritus, anaphylactic reaction.
Metabolism and nutrition disorders: Hypoglycaemia.
Psychiatric disorders: Insomnia, depression, nightmares, memory loss.
Nervous system disorders: Syncope, cerebrovascular accident, cerebral ischaemia, increase in signs and symptoms of myasthenia gravis, dizziness, paresthesia, and headache.
Eye disorders: Signs and symptoms of ocular irritation (e.g., burning, stinging, itching, tearing and redness), blepharitis, keratitis, blurred vision and choroidal detachment following filtration surgery (see Precautions), decreased corneal sensitivity, dry eyes, corneal erosion ptosis, diplopia.
Ear and labyrinth disorders: Tinnitus.
Cardiac disorders: Bradycardia, chest pain, palpitations, oedema, arrhythmia, congestive heart failure, atrioventricular block, cardiac arrest, cardiac failure.
Vascular disorders: Hypotension, Raynaud's phenomenon, cold hands and feet.
Respiratory, thoracic and mediastinal disorders: Bronchospasm (predominately in patients with pre-existing bronchospastic disease), dyspnoea, cough.
Gastrointestinal disorders: Dysgeusia, nausea, dyspepsia, diarrhoea, dry mouth, abdominal pain, vomiting.
Skin and subcutaneous tissue disorders: Alopecia, psoriasiform rash or exacerbation of psoriasis, skin rash.
Musculoskeletal and connective tissue disorders: Myalgia.
Reproductive system and breast disorders: Sexual dysfunction, decreased libido.
General disorders and administration site conditions: Asthenia/fatigue.
Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.